Evidence map›Paper›PMID 31685998›Full record

ArticleEuropean journal of human genetics : EJHG2020

Further delineation of neuropsychiatric findings in Tatton-Brown-Rahman syndrome due to disease-causing variants in DNMT3A: seven new patients.

Jair Tenorio, Pablo Alarcón, Pedro Arias, Irene Dapía, Sixto García-Miñaur, María Palomares Bralo, Jaume Campistol, Salvador Climent, Irene Valenzuela, Sergio Ramos and 18 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in European journal of human genetics : EJHG, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Alterations toCancer research · 2021
    Review
  15. The Epigenome in Neurodevelopmental Disorders.Frontiers in neuroscience · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 6 institutions in 2 countries.

Jair TenorioInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.ORCID http://orcid.org/0000-0002-5308-2316
Pablo AlarcónSección Genética, Hospital Clínico Universidad de Chile, Santos Dumont 999, Santiago, Chile.
Pedro AriasInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.
Irene DapíaInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.
Sixto García-MiñaurInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.
María Palomares BraloInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.ORCID http://orcid.org/0000-0002-2727-7654
Jaume CampistolDepartment of Neurology, Hospital Universitari Sant Joan de Déu, Barcelona, Spain.
Salvador ClimentDepartment of Pediatrics, Hospital General de Ontinyent, Valencia, Spain.
Irene ValenzuelaDepartment of Cardiology, Hospital Universitari Vall d'Hebron, CIBER-CV, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sergio RamosInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.
Antonio Martínez MonsenyDepartment of Genetics and Molecular Medicine and Rare Disease Paediatric Unit, Hospital Sant Joan de Déu, Barcelona, Spain.
Fermina López GrondonaDepartment of Cardiology, Hospital Universitari Vall d'Hebron, CIBER-CV, Universitat Autònoma de Barcelona, Barcelona, Spain.
Javier BotetNIMGENETICS, c/ Faraday, 7 Parque Científico de Madrid, 2804, Madrid, Spain.
Mercedes SerranoCIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
Mario SolísInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.ORCID http://orcid.org/0000-0002-9108-2835
Fernando Santos-SimarroInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.
Sara ÁlvarezNIMGENETICS, c/ Faraday, 7 Parque Científico de Madrid, 2804, Madrid, Spain.
Gisela Teixidó-TuraDepartment of Cardiology, Hospital Universitari Vall d'Hebron, CIBER-CV, Universitat Autònoma de Barcelona, Barcelona, Spain.
Alberto Fernández JaénDepartment of Pediatrics Neurology, Quirón Hospitals, Madrid, Spain.
Gema GordoInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.
María Belén Bardón RiveraDepartment of Psychiatry, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.
Julián NevadoInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.
Alicia HernándezInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain.
Juan C CigudosaNIMGENETICS, c/ Faraday, 7 Parque Científico de Madrid, 2804, Madrid, Spain.
Víctor L Ruiz-PérezCIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
Eduardo F TizzanoMolecular and Clinical Department, Hospital Valle Hebron, Pso. Vall d' Hebron, 119-129, Barcelona, Spain.
SOGRI Consortium
Pablo LapunzinaInstituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz-UAM, Paseo de La Castellana, 261, 28046, Madrid, Spain. pablo.lapunzina@salud.madrid.org.
Hospital Universitario La Paz · ESHospital Sant Joan de Déu Barcelona · ESUniversitat Autònoma de Barcelona · ESInstituto de Salud Carlos III · ESHospital Clínico de la Universidad de Chile · CLVall d'Hebron Hospital Universitari · ES

Funding

Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) FIS PI15/01481Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI15/1481
6 · The paper itself

Abstract

Tatton-Brown-Rahman (TBRS) syndrome is a recently described overgrowth syndrome caused by loss of function variants in the DNMT3A gene. This gene encodes for a DNA methyltransferase 3 alpha, which is involved in epigenetic regulation, especially during embryonic development. Somatic variants in DNMT3A have been widely studied in different types of tumors, including acute myeloid leukemia, hematopoietic, and lymphoid cancers. Germline gain-of-function variants in this gene have been recently implicated in microcephalic dwarfism. Common clinical features of patients with TBRS include tall stature, macrocephaly, intellectual disability (ID), and a distinctive facial appearance. Differential diagnosis of TBRS comprises Sotos, Weaver, and Malan Syndromes. The majority of these disorders present other clinical features with a high clinical overlap, making necessary a molecular confirmation of the clinical diagnosis. We here describe seven new patients with variants in DNMT3A, four of them with neuropsychiatric disorders, including schizophrenia and psychotic behavior. In addition, one of the patients has developed a brain tumor in adulthood. This patient has also cerebral atrophy, aggressive behavior, ID, and abnormal facial features. Clinical evaluation of this group of patients should include a complete neuropsychiatric assessment together with psychological support in order to detect and manage abnormal behaviors such as aggressiveness, impulsivity, and attention deficit-hyperactivity disorder. TBRS should be suspected in patients with overgrowth, ID, tall stature, and macrocephaly, who also have some neuropsychiatric disorders without any genetic defects in the commonest overgrowth disorders. Molecular confirmation in these patients is mandatory.

Indexed as

PhenotypeAdolescentAdultChildDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemaleGrowth DisordersHumansIntellectual DisabilityMaleMiddle AgedMutationPsychotic DisordersSyndromeDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, human

Identifiers

PMID31685998
PMCPMC7080728
OpenAlexW2988771575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.